3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Carcinoma, Non-Small-Cell Lung
10
Uterine Cervical Neoplasms
8
Squamous Cell Carcinoma of Head and Neck
6
Stomach Neoplasms
5
Triple Negative Breast Neoplasms
4
Carcinoma, Renal Cell
4
Advanced Solid Tumors
4
Urinary Bladder Neoplasms
3
Recurrence
3
Pancreatic Neoplasms
3
Melanoma
3
Lung Neoplasms
3
Solid Tumor
2
Ovarian Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Kidney Neoplasms
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Cholangiocarcinoma
2
Breast Neoplasms
2
Adenocarcinoma Of Esophagus
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Urothelial Bladder Carcinoma
1
Thyroid Carcinoma, Anaplastic
1
Thymoma
1
Solid Tumors
1
Solid Tumor, Unspecified, Adult
1
Sarcoma
1
Interventions
Cisplatin
7
Cetuximab
5
Radiotherapy
3
Drug Therapy
3
Resistance Training
2
Radiotherapy, Intensity-Modulated
2
Nutritional Status
2
Hydroxyurea
2
Fluorouracil
2
Erlotinib Hydrochloride
2
Bevacizumab
2
zimberelimab
1
temsirolimus
1
pembrolizumab
1
Valproic Acid
1
Sirolimus
1
Radiation
1
Psychology, Positive
1
Oncolytic Virotherapy
1
Methods
1
Immunoglobulin G
1
Etoposide
1
Docetaxel
1
Disulfides
1
Cyclophosphamide
1
Cryosurgery
1
Chemoradiotherapy
1
Celecoxib
1
Carboplatin
1
CP protocol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Pharyngeal Neoplasms
×
zimberelimab
×
Clear all
NCT04892875
2023-11-30
PANTHEoN
Vanderbilt-Ingram Cancer Center
Phase 1
Withdrawn